Luma Healthcare, Inc.

LumaHealthcare.com

Luma Healthcare was born out of the fact that no single source existed to go and get healthy. Our founders, whose backgrounds included Medicine, Clinical Research, Law, and Venture Capital, decided to rethink the problems of modern day Primary and Secondary Care, with the Patient As The Beneficiary. The result was the creation of Luma Healthcare, Inc. a healthcare technology - patient centric - platform.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SPRUCE BIOSCIENCES CLOSES ON $88 MILLION SERIES B ROUND, ADVANCING CAH PROGRAM

BioSpace | February 20, 2020

news image

Spruce Biosciences, based in San Francisco, closed on a Series B financing round worth $88 million. The round was co-led by Omega Funds and Abingworth and supported by existing investors Novo Holdings and RiverVest Venture Partners. New investors included HealthCap Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), Aisling Capital and Sands Capital. In September 2019, the company announced positive results from a Phase IIa, multicenter, 12-week clinical trial of tildacerfont f...

Read More

Cell and Gene Therapy, Industry Outlook

ADAPTIVE BIOTECHNOLOGIES ANNOUNCES FDA ACCEPTANCE OF GENENTECH’S INVESTIGATIONAL NEW DRUG APPLICATION FOR FIRST NEOANTIGEN-DIRECTED T-CELL THERAPY

Globenewswire | May 10, 2023

news image

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to detect and treat disease, announced that the U.S. Food and Drug Administration has accepted an investigational new drug (IND) application submitted by its collaborator, Genentech, a member of the Roche Group, for a T-cell receptor (TCR) based T-Cell Therapy. This is the first TCR-based therapeutic product candidate t...

Read More

TEVOGEN BIO PARTNERED WITH NEAL FLOMENBERG TO EVALUATE TEVOGEN' S PROPRIETARY ANTIGEN-SPECIFIC T-CELL TECHNOLOGY AS A TREATMENT FOR COVID-19

Tevogen Bio | August 11, 2020

news image

Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...

Read More

Cell and Gene Therapy, Industrial Impact

CBM ANNOUNCES PARTNERSHIP WITH VIRION THERAPEUTICS

Center for Breakthrough Medicines | February 27, 2023

news image

Center for Breakthrough Medicines (CBM), a leading contract development and manufacturing organization dedicated to addressing the challenges of commercializing cell and gene therapies, and Virion Therapeutics, a clinical-stage biotech firm focused on developing accessible and adaptable CD8+ T cell-based technologies for cancer and infectious diseases, have recently announced a strategic collaboration agreement. CBM will partner and manufacture with Virion Therapeutics on their ...

Read More
news image

SPRUCE BIOSCIENCES CLOSES ON $88 MILLION SERIES B ROUND, ADVANCING CAH PROGRAM

BioSpace | February 20, 2020

Spruce Biosciences, based in San Francisco, closed on a Series B financing round worth $88 million. The round was co-led by Omega Funds and Abingworth and supported by existing investors Novo Holdings and RiverVest Venture Partners. New investors included HealthCap Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), Aisling Capital and Sands Capital. In September 2019, the company announced positive results from a Phase IIa, multicenter, 12-week clinical trial of tildacerfont f...

Read More
news image

Cell and Gene Therapy, Industry Outlook

ADAPTIVE BIOTECHNOLOGIES ANNOUNCES FDA ACCEPTANCE OF GENENTECH’S INVESTIGATIONAL NEW DRUG APPLICATION FOR FIRST NEOANTIGEN-DIRECTED T-CELL THERAPY

Globenewswire | May 10, 2023

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to detect and treat disease, announced that the U.S. Food and Drug Administration has accepted an investigational new drug (IND) application submitted by its collaborator, Genentech, a member of the Roche Group, for a T-cell receptor (TCR) based T-Cell Therapy. This is the first TCR-based therapeutic product candidate t...

Read More
news image

TEVOGEN BIO PARTNERED WITH NEAL FLOMENBERG TO EVALUATE TEVOGEN' S PROPRIETARY ANTIGEN-SPECIFIC T-CELL TECHNOLOGY AS A TREATMENT FOR COVID-19

Tevogen Bio | August 11, 2020

Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...

Read More
news image

Cell and Gene Therapy, Industrial Impact

CBM ANNOUNCES PARTNERSHIP WITH VIRION THERAPEUTICS

Center for Breakthrough Medicines | February 27, 2023

Center for Breakthrough Medicines (CBM), a leading contract development and manufacturing organization dedicated to addressing the challenges of commercializing cell and gene therapies, and Virion Therapeutics, a clinical-stage biotech firm focused on developing accessible and adaptable CD8+ T cell-based technologies for cancer and infectious diseases, have recently announced a strategic collaboration agreement. CBM will partner and manufacture with Virion Therapeutics on their ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us